Advisory Committee Finds Insufficient Evidence for Duchenne’s Drug’s Efficacy

Drug Industry Daily
A A
An FDA advisory committee voted 10 to 1 Wednesday that a muscular dystrophy drug candidate does not have enough supporting data to be considered effective.

To View This Article:

Login

Subscribe To Drug Industry Daily